Opendata, web and dolomites

BabyLux

Launching the First Non-Invasive Brain-Monitoring System for the Early Detection and Management of Encephalopathy In Preterm Babies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BabyLux project word cloud

Explore the words cloud of the BabyLux project. It provides you a very rough idea of what is the project "BabyLux" about.

solutions    200m    solving    monitoring    first    20    smei    hospitals    turnover    anyhow    flow    cerebral    manner    partial    figures    blood    neonatal    gestation    reaching    credibility    preterm    born    despite    37    decades    15    months    over    artificial    lasting    sold    segments    entrance    period    impairments    metabolism    commercial    fact    time    detect    successful    babies    paralysis    neonates    damage    stage    failing    assumptions    until    model    affordable    worldwide    2014    disorders    units    leads    hemophotonics    maintaining    nicus    care    lifelong    intensive    sub    oxygen    alive    suffering    million    compilation    mixed    weeks    13    encephalopathies    unsolved    risk    markets    last    visual    easing    brain    babylux    tremendously    segment    community    extremely    premature       autism    corroborate    market    photonic    hearing    requesting    device    carg    business    commercialization    clinical    births    gestational    deficit    live    techniques    accurate    invasive    fall    combining    gain    precise    scientific   

Project "BabyLux" data sheet

The following table provides information about the project.

Coordinator
HEMOPHOTONICS SL 

Organization address
address: AVENIDA CARL FRIEDRICH GAUSS 3 OFICINA 346 MEDITERRANEAN TECHNOLOGY PARK
city: CASTELLDEFELS
postcode: 8860
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.hemophotonics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOPHOTONICS SL ES (CASTELLDEFELS) coordinator 50˙000.00

Map

 Project objective

Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments. To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques. Our product fall within the sub-segment of “monitoring equipment” for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BABYLUX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BABYLUX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

oWBI (2018)

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Read More  

BioAhead (2017)

BioAhead – an innovative optimization algorithm for amino acid chain analytics

Read More